NLRP3 and metabolic dysfunction-associated steatotic liver disease: Previous research has shown that inhibiting NLRP3 can help mitigate the activation of pyroptosis (Singla et al., 2019), and we have previously suggested that inhibiting NLRP3‐mediated pyroptosis can ameliorate NAFLD in rats (Li et al., 2021).